Novartis (NVS) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Barclays Upgrades Novartis (NVS) to Equalweight
April 22, 2016 7:43 AM EDTBarclays upgraded Novartis (NYSE: NVS) from Underweight to Equalweight.
For an analyst ratings summary and ratings history on Novartis click here. For more ratings news on Novartis click here.
Shares of Novartis closed at $76.28 yesterday.
... More